Levetiracetam Brown & Burk (Levetiracetam)

Levetiracetam exerts its antiepileptic effect by binding to the synaptic vesicle protein SV2A. This binding modulates neurotransmitter release, stabilizes neuronal firing, and diminishes hyper‑excitability in the brain, thereby lowering the likelihood of seizure propagation.

The dose of Levetiracetam Brown & Burk is individualized. A qualified prescriber determines the appropriate starting dose, titration schedule, and maintenance dose based on the patient’s age, renal function, seizure type, and clinical response. No fixed regimen is provided here.

Safety data for levetiracetam in pregnancy are limited, and the product is classified as having an unknown pregnancy category. It should be used only if the potential benefit outweighs any possible risk to the fetus. Breastfeeding mothers should consult their healthcare provider, as the drug is excreted in breast milk.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After the request, the sales team will verify trade or institutional credentials and respond with pricing, availability, shipping details, and any necessary import documentation.

Compared with older agents such as carbamazepine or valproate, levetiracetam has a distinct mechanism (SV2A binding) and generally fewer drug‑enzyme interactions, which simplifies combination therapy. It is often well‑tolerated, but clinicians still assess individual efficacy, side‑effect profile, and patient comorbidities when selecting therapy.

Store the tablets at ambient temperature, preferably below 25 °C. Keep the product in its original container, protect it from moisture and direct light, and ensure the packaging remains sealed until use. No refrigeration is required.

Levetiracetam Brown & Burk is taken orally. Tablets should be swallowed whole with a glass of water and may be taken with or without food, according to the prescriber’s instructions. Consistent timing helps maintain stable blood levels.

Serious adverse reactions include severe allergic responses such as Stevens‑Johnson syndrome, marked mood alterations (including depression or suicidal ideation), and rare hematologic abnormalities like leukopenia. Patients should be monitored closely for any new or worsening psychiatric symptoms or skin reactions.

Levetiracetam is contraindicated in patients with known hypersensitivity to levetiracetam or any of its excipients. Caution is advised for individuals with severe renal impairment, uncontrolled psychiatric disorders, or those taking interacting medications that significantly lower its plasma concentration.